Yili Chuannig Biotech - Public Comps and Valuation Multiples

Yili Chuannig Biotech Overview

About Yili Chuannig Biotech

Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.

Founded

2010

HQ

Employees

n/a

Website

klcnsw.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $674M

LTM EBITDA $212M

EV

$3.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Yili Chuannig Biotech Financials

As of November 2025, Yili Chuannig Biotech reported last 12-month revenue of $674M and EBITDA of $212M.

In the same period, Yili Chuannig Biotech generated $220M in LTM gross profit and $128M in net income.

See Yili Chuannig Biotech valuation multiples based on analyst estimates

Yili Chuannig Biotech P&L

In the most recent fiscal year, Yili Chuannig Biotech reported revenue of $814M and EBITDA of $322M.

Yili Chuannig Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Yili Chuannig Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$674M	XXX	$814M	XXX	XXX	XXX
Gross Profit	$220M	XXX	$296M	XXX	XXX	XXX
Gross Margin	33%	XXX	36%	XXX	XXX	XXX
EBITDA	$212M	XXX	$322M	XXX	XXX	XXX
EBITDA Margin	31%	XXX	40%	XXX	XXX	XXX
EBIT	$156M	XXX	$248M	XXX	XXX	XXX
EBIT Margin	23%	XXX	30%	XXX	XXX	XXX
Net Profit	$128M	XXX	$198M	XXX	XXX	XXX
Net Margin	19%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Yili Chuannig Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $674M. EBITDA for the last twelve months was $212M. In the most recent fiscal year, Yili Chuannig Biotech achieved $814M in revenue and $322M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$674M	Analyst estimates available to subscribers	$814M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$220M	Analyst estimates available to subscribers	$296M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	32.6% gross margin	Analyst estimates available to subscribers	36.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$212M	Analyst estimates available to subscribers	$322M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	31.4% EBITDA margin	Analyst estimates available to subscribers	39.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$156M	Analyst estimates available to subscribers	$248M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	23.1% EBIT margin	Analyst estimates available to subscribers	30.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$128M	Analyst estimates available to subscribers	$198M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	19.0% net profit margin	Analyst estimates available to subscribers	24.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Yili Chuannig Biotech

This financial data table provides comprehensive performance metrics for Yili Chuannig Biotech, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Yili Chuannig Biotech generated $674M in revenue over the last twelve months.
The company achieved $212M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $220M.
Net income over the last twelve months reached $128M.

Fiscal Year Performance

In the most recent fiscal year, Yili Chuannig Biotech reported $814M in total revenue.
Fiscal year EBITDA was $322M.
The company maintained a gross profit margin of 36.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 39.6%.
Net profit margin reached 24.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Yili Chuannig Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Yili Chuannig Biotech Stock Performance

Yili Chuannig Biotech has current market cap of CNY 23.0B (or $3.3B), and EV of CNY 23.5B (or $3.3B).

Market Cap Evolution

Yili Chuannig Biotech Stock Data

As of December 3, 2025, Yili Chuannig Biotech's stock price is CNY 10 (or $1).

See Yili Chuannig Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.3B	$3.3B	XXX	XXX	XXX	XXX	$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Yili Chuannig Biotech Valuation Multiples

Yili Chuannig Biotech's trades at 4.1x EV/Revenue multiple, and 10.3x EV/EBITDA.

See valuation multiples for Yili Chuannig Biotech and 15K+ public comps

Yili Chuannig Biotech Financial Valuation Multiples

As of December 3, 2025, Yili Chuannig Biotech has market cap of $3.3B and EV of $3.3B.

Equity research analysts estimate Yili Chuannig Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Yili Chuannig Biotech has a P/E ratio of 25.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.3B	XXX	$3.3B	XXX	XXX	XXX
EV (current)	$3.3B	XXX	$3.3B	XXX	XXX	XXX
EV/Revenue	4.9x	XXX	4.1x	XXX	XXX	XXX
EV/EBITDA	15.7x	XXX	10.3x	XXX	XXX	XXX
EV/EBIT	21.3x	XXX	13.4x	XXX	XXX	XXX
EV/Gross Profit	15.1x	XXX	n/a	XXX	XXX	XXX
P/E	25.3x	XXX	16.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	13.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Yili Chuannig Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Yili Chuannig Biotech Margins & Growth Rates

Yili Chuannig Biotech's last 12 month revenue growth is 6%

Yili Chuannig Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Yili Chuannig Biotech's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yili Chuannig Biotech's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Yili Chuannig Biotech and other 15K+ public comps

Yili Chuannig Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	-6%	XXX	XXX	XXX
EBITDA Margin	31%	XXX	40%	XXX	XXX	XXX
EBITDA Growth	23%	XXX	-4%	XXX	XXX	XXX
Rule of 40	43%	XXX	46%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	48%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	6%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial